Determinants and Effectiveness of Extending the Duration of Adjuvant Hormone Therapy beyond 5 Years in Patients with Breast Cancer

Clinical guidelines have recommended patients with high-risk breast cancer to extend adjuvant hormone therapy beyond 5 years. However, the prevalence, predictors, and outcomes of extended adjuvant hormone therapy in the real world remain unknown. By linking six Swedish health registries, we prospect...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Erwei, He, Wei, Sjölander, Arvid, Bergqvist, Jenny, Czene, Kamila
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Translational Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530643/
https://www.ncbi.nlm.nih.gov/pubmed/35980311
http://dx.doi.org/10.1158/0008-5472.CAN-22-0900

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530643/
https://www.ncbi.nlm.nih.gov/pubmed/35980311
http://dx.doi.org/10.1158/0008-5472.CAN-22-0900

Ejemplares similares